These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19749756)

  • 61. Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.
    Ling Q; Chen J; Zhou H; Zhong J; Chen Y; Ye Q; Zhuo Y; Min N; Shang B
    Arch Virol; 2015 Apr; 160(4):1105-12. PubMed ID: 25687192
    [TBL] [Abstract][Full Text] [Related]  

  • 62. IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients.
    Venegas M; Villanueva RA; González K; Brahm J
    World J Gastroenterol; 2011 Aug; 17(31):3636-9. PubMed ID: 21987611
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
    Jung YK; Kim JH; Ahn SM; Yang JW; Park SJ; Kim JW; Yeon JE; Kwon OS; Kim YS; Choi DJ; Kim JH; Byun KS
    J Clin Gastroenterol; 2013 Aug; 47(7):644-50. PubMed ID: 23442843
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?
    Garcia RF; Moreira S; de Araújo Ramos AL; Ferreira LE; de Mattos AA; Tovo CV; Nader LA; Ramos JA; Rondinelli E; de Jesus Dominici A; Garcia CE; de Souza Leite Pinho M; Brandão-Mello CE; Villela-Nogueira CA; de França PH
    World J Gastroenterol; 2013 Nov; 19(42):7399-404. PubMed ID: 24259970
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study.
    Peng CY; Chen TH; Lim YP; Tsai FJ; Lin WY; Liao WL; Wan L
    BMC Gastroenterol; 2014 Jun; 14():113. PubMed ID: 24969847
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
    McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
    Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.
    Jia Z; Ding Y; Tian S; Niu J; Jiang J
    PLoS One; 2012; 7(9):e45698. PubMed ID: 23029188
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PharmGKB summary: peginterferon-α pathway.
    Shuldiner SR; Gong L; Muir AJ; Altman RB; Klein TE
    Pharmacogenet Genomics; 2015 Sep; 25(9):465-74. PubMed ID: 26111151
    [No Abstract]   [Full Text] [Related]  

  • 71. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
    Izumi N; Yokosuka O; Kawada N; Osaki Y; Yamamoto K; Sata M; Ishikawa H; Ueki T; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):501-10. PubMed ID: 24451151
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.
    Murata K; Sugiyama M; Kimura T; Yoshio S; Kanto T; Kirikae I; Saito H; Aoki Y; Hiramine S; Matsui T; Ito K; Korenaga M; Imamura M; Masaki N; Mizokami M
    J Gastroenterol; 2014 Jan; 49(1):126-37. PubMed ID: 23591768
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Host genomics and HCV treatment response.
    Clark PJ; Thompson AJ
    J Gastroenterol Hepatol; 2012 Feb; 27(2):212-22. PubMed ID: 21916985
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype.
    Guo X; Zhao Z; Xie J; Cai Q; Zhang X; Peng L; Gao Z
    Virol J; 2012 Jun; 9():123. PubMed ID: 22713131
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
    Younossi ZM; Birerdinc A; Estep M; Stepanova M; Afendy A; Baranova A
    J Transl Med; 2012 Feb; 10():25. PubMed ID: 22313623
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
    Honda M; Sakai A; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shirasaki T; Horimoto K; Tanaka Y; Tokunaga K; Mizokami M; Kaneko S;
    Gastroenterology; 2010 Aug; 139(2):499-509. PubMed ID: 20434452
    [TBL] [Abstract][Full Text] [Related]  

  • 78. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.
    Martínez-Gómez LE; Chávez-Tapia NC; Burguete-García AI; Aguilar-Olivos N; Madrid-Marina V; Román-Bahena M; Orbe-Orihuela C; Misael U; Méndez-Sánchez N
    Ann Hepatol; 2012; 11(6):876-81. PubMed ID: 23109451
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Boceprevir for chronic HCV genotype 1 infection.
    Hsu CS; Kao JH
    N Engl J Med; 2011 Jul; 365(2):176-7; author reply 177-8. PubMed ID: 21751913
    [No Abstract]   [Full Text] [Related]  

  • 80. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.
    Cariani E; Roli L; Missale G; Villa E; Ferrari C; Trenti T
    Pharmacogenomics J; 2016 Feb; 16(1):18-29. PubMed ID: 25918016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.